Solodyn

Manufacturer
Physicians Total Care, Inc.
Effective date
2011-04-04
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:12:25

Label at a glance#

ProductSolodyn
Active ingredientminocycline hydrochloride
Label structure18 sections

Indications and uses

SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. SOLODYN did not demonstrate any effect on non-inflammatory acne lesions. Safety of SOLODYN has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections [see Clinical Studies (14) ] . To reduce the dev...

Dosage and administration

The recommended dosage of SOLODYN is approximately 1 mg/kg once daily for 12 weeks. Higher doses have not shown to be of additional benefit in the treatment of inflammatory lesions of acne, and may be associated with more acute vestibular side effects. The following table shows tablet strength and body weight to achieve approximately 1 mg/kg. Table 1: Dosing Table for SOLODYN Patient's Weight (lbs.) Patient's Weig...

Storage and handling

SOLODYN (minocycline HCl, USP) Extended Release Tablets are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 80 mg minocycline, are supplied as follows. The 80 mg extended release tablets are gray, unscored, coated, and debossed with "DYN-080" on one side. Each tablet contains minocycline hydrochloride equivalent to 80 mg minocycline, supplied as follows: NDC 54868-6285-0 ...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

1.1 Indication

SPL UNCLASSIFIED SECTION

SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

1.2 Limitations of Use

SPL UNCLASSIFIED SECTION

SOLODYN did not demonstrate any effect on non-inflammatory acne lesions. Safety of SOLODYN has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections [see Clinical Studies (14)].

To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SOLODYN should be used only as indicated [see Warnings and Precautions (5.11)].

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended dosage of SOLODYN is approximately 1 mg/kg once daily for 12 weeks. Higher doses have not shown to be of additional benefit in the treatment of inflammatory lesions of acne, and may be associated with more acute vestibular side effects.

The following table shows tablet strength and body weight to achieve approximately 1 mg/kg.

Table 1: Dosing Table for SOLODYN
Patient's Weight (lbs.)Patient's Weight (kg)Tablet Strength (mg)Actual mg/kg Dose
99 – 10945 – 49451 – 0.92
110 – 13150 – 59551.10 – 0.93
132 – 15760 – 71651.08 – 0.92
158 – 18672 – 84801.11 – 0.95
187 – 21285 – 96901.06 – 0.94
213 – 24397 – 1101051.08 – 0.95
244 – 276111 – 1251151.04 – 0.92
277 – 300126 – 1361351.07 – 0.99

SOLODYN Tablets may be taken with or without food [see Clinical Pharmacology (12)]. Ingestion of food along with SOLODYN may help reduce the risk of esophageal irritation and ulceration.

In patients with renal impairment, the total dosage should be decreased by either reducing the recommended individual doses and/or by extending the time intervals between doses [see Warnings and Precautions (5.4)].

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

  • 45 mg extended release tablets: gray, unscored, coated, and debossed with "DYN-045" on one side.
  • 55 mg extended release tablets: pink, unscored, coated, and debossed with "DYN-055" on one side.
  • 65 mg extended release tablets: blue, unscored, coated, and debossed with "DYN-065" on one side.
  • 80 mg extended release tablets: gray, unscored, coated, and debossed with "DYN-080" on one side.
  • 90 mg extended release tablets: yellow, unscored, coated, and debossed with "DYN-090" on one side.
  • 105 mg extended release tablets: purple, unscored, coated, and debossed with "DYN-105" on one side.
  • 115 mg extended release tablets: green, unscored, coated, and debossed with "DYN-115" on one side.
  • 135 mg extended release tablets: pink (orange-brown), unscored, coated, and debossed with "DYN-135" on one side.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Teratogenic Effects

TERATOGENIC EFFECTS SECTION

  1. MINOCYCLINE, LIKE OTHER TETRACYCLINE-CLASS DRUGS, CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. IF ANY TETRACYCLINE IS USED DURING PREGNANCY OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE DRUGS, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS.

    SOLODYN should not be used during pregnancy or by individuals of either gender who are attempting to conceive a child [see Nonclinical Toxicology (13.1) & Use in Specific Populations (8.1)].
  2. THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD UP TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN).

    This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED DURING TOOTH DEVELOPMENT.
  3. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.

    Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can cause retardation of skeletal development on the developing fetus. Evidence of embryotoxicity has been noted in animals treated early in pregnancy [ see Use in Specific Populations (8.1)].

5.2 Pseudomembranous Colitis

SPL UNCLASSIFIED SECTION

Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of "antibiotic-associated colitis".

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against Clostridium difficile colitis.

5.3 Hepatotoxicity

SPL UNCLASSIFIED SECTION

Post-marketing cases of serious liver injury, including irreversible drug-induced hepatitis and fulminant hepatic failure (sometimes fatal) have been reported with minocycline use in the treatment of acne.

5.4 Metabolic Effects

SPL UNCLASSIFIED SECTION

The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline-class drugs may lead to azotemia, hyperphosphatemia, and acidosis. If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated, and if therapy is prolonged, serum level determinations of the drug may be advisable.

5.5 Central Nervous System Effects

SPL UNCLASSIFIED SECTION

Central nervous system side effects including light-headedness, dizziness or vertigo have been reported with minocycline therapy. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. These symptoms may disappear during therapy and usually rapidly disappear when the drug is discontinued.

5.6 Benign Intracranial Hypertension

SPL UNCLASSIFIED SECTION

Pseudotumor cerebri (benign intracranial hypertension) in adults and adolescents has been associated with the use of tetracyclines. Minocycline has been reported to cause or precipitate pseudotumor cerebri, the hallmark of which is papilledema. Clinical manifestations include headache and blurred vision. Bulging fontanels have been associated with the use of tetracyclines in infants. Although signs and symptoms of pseudotumor cerebri resolve after discontinuation of treatment, the possibility for permanent sequelae such as visual loss that may be permanent or severe exists. Patients should be questioned for visual disturbances prior to initiation of treatment with tetracyclines. If visual disturbance occurs during treatment, patients should be checked for papilledema. Concomitant use of isotretinoin and minocycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri.

5.7 Autoimmune Syndromes

SPL UNCLASSIFIED SECTION

Tetracyclines have been associated with the development of autoimmune syndromes. The long-term use of minocycline in the treatment of acne has been associated with drug-induced lupus-like syndrome, autoimmune hepatitis and vasculitis. Sporadic cases of serum sickness have presented shortly after minocycline use. Symptoms may be manifested by fever, rash, arthralgia, and malaise. In symptomatic patients, liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. Use of all tetracycline-class drugs should be discontinued immediately.

5.8 Photosensitivity

SPL UNCLASSIFIED SECTION

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. This has been reported rarely with minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using minocycline. If patients need to be outdoors while using minocycline, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician.

5.9 Serious Skin/Hypersensitivity Reaction

SPL UNCLASSIFIED SECTION

Cases of anaphylaxis, serious skin reactions (e.g. Stevens Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported postmarketing with minocycline use in patients with acne. DRESS syndrome consists of cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more of the following visceral complications such as: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis. Fever and lymphadenopathy may be present. In some cases, death has been reported. If this syndrome is recognized, the drug should be discontinued immediately.

5.10 Tissue Hyperpigmentation

SPL UNCLASSIFIED SECTION

Tetracycline-class antibiotics are known to cause hyperpigmentation. Tetracycline therapy may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. Skin and oral pigmentation has been reported to occur independently of time or amount of drug administration, whereas other tissue pigmentation has been reported to occur upon prolonged administration. Skin pigmentation includes diffuse pigmentation as well as over sites of scars or injury.

5.11 Development of Drug-Resistant Bacteria

SPL UNCLASSIFIED SECTION

Bacterial resistance to the tetracyclines may develop in patients using SOLODYN, therefore, the susceptibility of bacteria associated with infection should be considered in selecting antimicrobial therapy. Because of the potential for drug-resistant bacteria to develop during the use of SOLODYN, it should be used only as indicated.

5.12 Superinfection

SPL UNCLASSIFIED SECTION

As with other antibiotic preparations, use of SOLODYN may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, SOLODYN should be discontinued and appropriate therapy instituted.

5.13 Laboratory Monitoring

SPL UNCLASSIFIED SECTION

Periodic laboratory evaluations of organ systems, including hematopoetic renal and hepatic studies should be performed. Appropriate tests for autoimmune syndromes should be performed as indicated.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

6.1 Clinical Trial Experience

SPL UNCLASSIFIED SECTION

Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not reflect the rates observed in practice.

The following table summarizes selected adverse reactions reported in clinical trials at a rate of ≥ 1% for SOLODYN.

Table 2: Selected Treatment-Emergent Adverse Reactions in at least 1% of Clinical Trial Subjects
Adverse ReactionsSOLODYN
(1 mg/kg)
N = 674 (%)
PLACEBO
N = 364 (%)
At least one treatment-emergent event379 (56)197 (54)
Headache152 (23)83 (23)
Fatigue62 (9)24 (7)
Dizziness59 (9)17 (5)
Pruritus31 (5)16 (4)
Malaise26 (4)9 (3)
Mood alteration17 (3)9 (3)
Somnolence13 (2)3 (1)
Urticaria10 (2)1 (0)
Tinnitus10 (2)5 (1)
Arthralgia9 (1)2 (0)
Vertigo8 (1)3 (1)
Dry mouth7 (1)5 (1)
Myalgia7 (1)4 (1)

6.2 Postmarketing Experience

SPL UNCLASSIFIED SECTION

Adverse reactions that have been reported with minocycline hydrochloride use in a variety of indications include:

  • Skin and hypersensitivity reactions: fixed drug eruptions, balanitis, erythema multiforme, Stevens-Johnson syndrome, anaphylactoid purpura, photosensitivity, pigmentation of skin and mucous membranes, hypersensitivity reactions, angioneurotic edema, anaphylaxis, DRESS syndrome [see Warnings and Precautions (5.9)].
  • Autoimmune conditions: polyarthralgia, pericarditis, exacerbation of systemic lupus, pulmonary infiltrates with eosinophilia, transient lupus-like syndrome.
  • Central nervous system: pseudotumor cerebri, bulging fontanels in infants, decreased hearing.
  • Endocrine: brown-black microscopic thyroid discoloration, abnormal thyroid function.
  • Oncology: thyroid cancer.
  • Oral: glossitis, dysphagia, tooth discoloration.
  • Gastrointestinal: enterocolitis, pancreatitis, hepatitis, liver failure.
  • Renal: reversible acute renal failure.
  • Hematology: hemolytic anemia, thrombocytopenia, eosinophilia.

Preliminary studies suggest that use of minocycline may have deleterious effects on human spermatogenesis [see Nonclinical Toxicology (13.1)].

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

7.1 Anticoagulants

SPL UNCLASSIFIED SECTION

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

7.2 Penicillin

SPL UNCLASSIFIED SECTION

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin.

7.3 Methoxyflurane

SPL UNCLASSIFIED SECTION

The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.

7.4 Antacids and Iron Preparations

SPL UNCLASSIFIED SECTION

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.

7.5 Low Dose Oral Contraceptives

SPL UNCLASSIFIED SECTION

In a multi-center study to evaluate the effect of SOLODYN on low dose oral contraceptives, hormone levels over one menstrual cycle with and without SOLODYN 1 mg/kg once-daily were measured. Based on the results of this trial, minocycline-related changes in estradiol, progestinic hormone, FSH and LH plasma levels, of breakthrough bleeding, or of contraceptive failure, can not be ruled out. To avoid contraceptive failure, female patients are advised to use a second form of contraceptive during treatment with minocycline.

7.6 Drug/Laboratory Test Interactions

DRUG & OR LABORATORY TEST INTERACTIONS SECTION

False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

TERATOGENIC EFFECTS SECTION

Teratogenic Effects: Pregnancy category D [see Warnings and Precautions (5.1)]

SOLODYN should not be used during pregnancy. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and stop treatment immediately.

There are no adequate and well-controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline-class drugs, crosses the placenta and may cause fetal harm when administered to a pregnant woman.

Rare spontaneous reports of congenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. Only limited information is available regarding these reports; therefore, no conclusion on causal association can be established.

Minocycline induced skeletal malformations (bent limb bones) in fetuses when administered to pregnant rats and rabbits in doses of 30 mg/kg/day and 100 mg/kg/day, respectively, (resulting in approximately 3 times and 2 times, respectively, the systemic exposure to minocycline observed in patients as a result of use of SOLODYN). Reduced mean fetal body weight was observed in studies in which minocycline was administered to pregnant rats at a dose of 10 mg/kg/day (which resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use SOLODYN).

Minocycline was assessed for effects on peri- and post-natal development of rats in a study that involved oral administration to pregnant rats from day 6 of gestation through the period of lactation (postpartum day 20), at dosages of 5, 10, or 50 mg/kg/day. In this study, body weight gain was significantly reduced in pregnant females that received 50 mg/kg/day (resulting in approximately 2.5 times the systemic exposure to minocycline observed in patients as a result of use of SOLODYN). No effects of treatment on the duration of the gestation period or the number of live pups born per litter were observed. Gross external anomalies observed in F1 pups (offspring of animals that received minocycline) included reduced body size, improperly rotated forelimbs, and reduced size of extremities. No effects were observed on the physical development, behavior, learning ability, or reproduction of F1 pups, and there was no effect on gross appearance of F2 pups (offspring of F1 animals).

8.3 Nursing Mothers

NURSING MOTHERS SECTION

Tetracycline-class antibiotics are excreted in human milk. Because of the potential for serious adverse effects on bone and tooth development in nursing infants from the tetracycline-class antibiotics, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother [see Warnings and Precautions (5.1)].

8.4 Pediatric Use

PEDIATRIC USE SECTION

SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years and older. Safety and effectiveness in pediatric patients below the age of 12 has not been established.

Use of tetracycline-class antibiotics below the age of 8 is not recommended due to the potential for tooth discoloration [see Warnings and Precautions (5.1)].

8.5 Geriatric Use

GERIATRIC USE SECTION

Clinical studies of SOLODYN did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.

10 OVERDOSAGE

OVERDOSAGE SECTION

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Minocycline is not removed in significant quantities by hemodialysis or peritoneal dialysis.

11 DESCRIPTION

DESCRIPTION SECTION

Minocycline hydrochloride, a semi synthetic derivative of tetracycline, is [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono hydrochloride. The structural formula is represented below:

C23H27N3O7•HCl      M. W. 493.95C23H27N3O7•HCl      M. W. 493.95

SOLODYN Tablets for oral administration contain minocycline hydrochloride USP equivalent to 45 mg, 55 mg, 65 mg, 80 mg, 90 mg, 105 mg, 115 mg, or 135 mg of minocycline. In addition, 45 mg, 55 mg, 65 mg, 80 mg, 90 mg, 105 mg, 115 mg, and 135 mg tablets contain the following inactive ingredients: lactose monohydrate NF, hypromellose type 2910 USP, magnesium stearate NF, colloidal silicon dioxide NF, and carnauba wax NF. The 45 mg tablets also contain Opadry II Gray which contains: lactose monohydrate NF, hypromellose type 2910 USP, titanium dioxide USP, triacetin USP, and iron oxide black JPE. The 55 mg tablets also contain Opadry II Pink which contains: hypromellose type 2910 USP, titanium dioxide USP, lactose monohydrate NF, polyethylene glycol 3350 NF, triacetin USP, and FD&C Red #40. The 65 mg tablets also contain Opadry II Blue which contains: hypromellose type 2910 USP, lactose monohydrate NF, FD&C Blue #1, polyethylene glycol 3350 NF, FD&C Blue #2, titanium dioxide USP, triacetin USP, and D&C Yellow #10. The 80 mg tablets also contain Opadry II Gray which contains: hypromellose type 2910 USP, lactose monohydrate NF, polyethylene glycol 3350 NF, FD&C Blue #2, FD&C Red #40, titanium dioxide USP, triacetin USP, and FD&C Yellow #6. The 90 mg tablets also contain Opadry II Yellow which contains: hypromellose type 2910 USP, lactose monohydrate NF, titanium dioxide USP, iron oxide yellow NF, polyethylene glycol 3350 NF, and triacetin USP. The 105 mg tablets also contain Opadry II Purple which contains: hypromellose type 2910 USP, lactose monohydrate NF, titanium dioxide USP, D&C Red #27, polyethylene glycol 3350 NF, triacetin USP, and FD&C Blue #1. The 115 mg tablets also contain Opadry II Green which contains: hypromellose type 2910 USP, lactose monohydrate NF, D&C Yellow #10, triacetin USP, FD&C Blue #1, titanium dioxide USP, and FD&C Blue #2. The 135 mg tablets also contain Opadry II Pink which contains: hypromellose type 2910 USP, lactose monohydrate NF, titanium dioxide USP, polyethylene glycol 3350 NF, iron oxide red NF, and triacetin USP.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

The mechanism of action of SOLODYN for the treatment of acne is unknown.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

The pharmacodynamics of SOLODYN for the treatment of acne are unknown.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

SOLODYN Tablets are not bioequivalent to non-modified release minocycline products. Based on pharmacokinetic studies in healthy adults, SOLODYN Tablets produce a delayed Tmax at 3.5–4.0 hours as compared to a non-modified release reference minocycline product (Tmax at 2.25–3 hours). At steady-state (Day 6), the mean AUC(0–24) and Cmax were 33.32 µg×hr/mL and 2.63 µg/mL for SOLODYN Tablets and 46.35 µg×hr/mL and 2.92 µg/mL for Minocin® capsules, respectively. These parameters are based on dose adjusted to 135 mg per day for both products.

A single-dose, four-way crossover study demonstrated that SOLODYN Tablets used in the study (45 mg, 90 mg, 135 mg) exhibited dose-proportional pharmacokinetics. In another single-dose, five-way crossover pharmacokinetic study, SOLODYN Tablets 55 mg, 80 mg, and 105 mg were shown to be dose-proportional to SOLODYN Tablets 90 mg and 135 mg.

When SOLODYN Tablets were administered concomitantly with a meal that included dairy products, the extent and timing of absorption of minocycline did not differ from that of administration under fasting conditions.

Minocycline is lipid soluble and distributes into the skin and sebum.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

SPL UNCLASSIFIED SECTION

Carcinogenesis—Long-term animal studies have not been performed to evaluate the carcinogenic potential of minocycline. A structurally related compound, oxytetracycline, was found to produce adrenal and pituitary tumors in rats.

SPL UNCLASSIFIED SECTION

Mutagenesis—Minocycline was not mutagenic in vitro in a bacterial reverse mutation assay (Ames test) or CHO/HGPRT mammalian cell assay in the presence or absence of metabolic activation. Minocycline was not clastogenic in vitro using human peripheral blood lymphocytes or in vivo in a mouse micronucleus test.

SPL UNCLASSIFIED SECTION

Impairment of Fertility—Male and female reproductive performance in rats was unaffected by oral doses of minocycline of up to 300 mg/kg/day (which resulted in up to approximately 40 times the level of systemic exposure to minocycline observed in patients as a result of use of SOLODYN). However, oral administration of 100 or 300 mg/kg/day of minocycline to male rats (resulting in approximately 15 to 40 times the level of systemic exposure to minocycline observed in patients as a result of use of SOLODYN) adversely affected spermatogenesis. Effects observed at 300 mg/kg/day included a reduced number of sperm cells per gram of epididymis, an apparent reduction in the percentage of sperm that were motile, and (at 100 and 300 mg/kg/day) increased numbers of morphologically abnormal sperm cells. Morphological abnormalities observed in sperm samples included absent heads, misshapen heads, and abnormal flagella.

Limited human studies suggest that minocycline may have a deleterious effect on spermatogenesis.

SOLODYN should not be used by individuals of either gender who are attempting to conceive a child.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

The safety and efficacy of SOLODYN in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris was assessed in two 12-week, multi-center, randomized, double-blind, placebo-controlled, studies in subjects ≥ 12 years. The mean age of subjects was 20 years and subjects were from the following racial groups: White (73%), Hispanic (13%), Black (11%), Asian/Pacific Islander (2%), and Other (2%).

In two efficacy and safety trials, a total of 924 subjects with non-nodular moderate to severe acne vulgaris received SOLODYN or placebo for a total of 12 weeks, according to the following dose assignments.

Table 3: Clinical Studies Dosing Table
Subject's Weight (lbs.)Subject's Weight (kg)Available Caplet Strength (mg)Actual mg/kg Dose
99 – 13145 – 59451 – 0.76
132 – 19960 – 90901.5 – 1
200 – 30091 – 1361351.48 – 0.99

The two primary efficacy endpoints were:

  • Mean percent change in inflammatory lesion counts from Baseline to 12 weeks.
  • Percentage of subjects with an Evaluator's Global Severity Assessment (EGSA) of clear or almost clear at 12 weeks.
    Efficacy results are presented in Table 4.
Table 4: Efficacy Results at Week 12
Study 1Study 2
SOLODYN
(1 mg/kg)
N = 300
Placebo
N = 151
SOLODYN
(1 mg/kg)
N = 315
Placebo
N = 158
Mean Percent Improvement in Inflammatory Lesions43.1%31.7%45.8%30.8%
No. (%) of Subjects Clear or Almost Clear on the EGSA 52
(17.3%)
12
(7.9%)
50
(15.9%)
15
(9.5%)

SOLODYN did not demonstrate any effect on non-inflammatory lesions (benefit or worsening).

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

16.1 How Supplied

SPL UNCLASSIFIED SECTION

SOLODYN (minocycline HCl, USP) Extended Release Tablets are supplied as aqueous film coated tablets containing minocycline hydrochloride equivalent to 80 mg minocycline, are supplied as follows.

The 80 mg extended release tablets are gray, unscored, coated, and debossed with "DYN-080" on one side. Each tablet contains minocycline hydrochloride equivalent to 80 mg minocycline, supplied as follows:

NDC 54868-6285-0Bottle of 30

16.2 Storage

STORAGE AND HANDLING SECTION

Store at 25°C (77°F); excursions are permitted to 15°–30°C (59°–86°F) [See USP Controlled Room Temperature].

16.3 Handling

STORAGE AND HANDLING SECTION

Keep out of reach of children.

Protect from light, moisture, and excessive heat.

Dispense in tight, light-resistant container with child-resistant closure.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

[See FDA-approved patient labeling (Patient Information)]

Patients taking SOLODYN (minocycline HCl, USP) Extended Release Tablets should receive the following information and instructions:

  • SOLODYN should not be used by pregnant women or women attempting to conceive a child [see Use in Specific Populations (8.1), Nonclinical Toxicology (13.1)].
  • It is recommended that SOLODYN not be used by men who are attempting to father a child [see Nonclinical Toxicology (13.1)].
  • Patients should be advised that pseudomembranous colitis can occur with minocycline therapy. If patients develop watery or bloody stools, they should seek medical attention.
  • Patients should be counseled about the possibility of hepatotoxicity. Patients should seek medical advice if they experience symptoms which can include loss of appetite, tiredness, diarrhea, skin turning yellow, bleeding easily, confusion, and sleepiness.
  • Patients who experience central nervous system symptoms [see Warnings and Precautions (5.5)] should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. Patients should seek medical help for persistent headaches or blurred vision.
  • Concurrent use of tetracycline may render oral contraceptives less effective [see Drug Interactions (7.5)].
  • Autoimmune syndromes, including drug-induced lupus-like syndrome, autoimmune hepatitis, vasculitis and serum sickness have been observed with tetracycline-class drugs, including minocycline. Symptoms may be manifested by arthralgia, fever, rash and malaise. Patients who experience such symptoms should be cautioned to stop the drug immediately and seek medical help.
  • Patients should be counseled about discoloration of skin, scars, teeth or gums that can arise from minocycline therapy.
  • Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines, including minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using minocycline. If patients need to be outdoors while using minocycline, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. Treatment should be discontinued at the first evidence of skin erythema.
  • SOLODYN should be taken exactly as directed. Skipping doses or not completing the full course of therapy may decrease the effectiveness of the current treatment course and increase the likelihood that bacteria will develop resistance and will not be treatable by other antibacterial drugs in the future.
  • Patients should be advised to swallow SOLODYN Tablets whole and not to chew, crush, or split the tablets.

SPL PATIENT PACKAGE INSERT SECTION

Patient Information
SOLODYN® (SO-lo-dīn)
(minocycline HCl)
Extended Release Tablets

Read this Patient Information leaflet that comes with SOLODYN before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.

What is SOLODYN?

SOLODYN is a tetracycline-class drug. SOLODYN is prescription medicine used to treat pimples and red bumps (non-nodular inflammatory lesions) that happen with moderate to severe acne vulgaris in people 12 years and older. SOLODYN is not effective for acne that is not red-looking (this means acne that is not inflammatory).

It is not known if SOLODYN is:

  • safe for use longer than 12 weeks.
  • safe and effective for the treatment of infections.
  • safe and effective in children under the age of 12 years.

Who should not take SOLODYN?

Do not take SOLODYN if you are allergic to tetracycline-class drugs. Ask your doctor or pharmacist for a list of these medicines if you are not sure.

What should I tell my doctor before taking SOLODYN?

Before you take SOLODYN, tell your doctor if you:

  • have kidney problems. Your doctor may prescribe a lower dose of medicine for you.
  • have liver problems.
  • have diarrhea or watery stools.
  • have vision problems.
  • plan to have surgery with general anesthesia.
  • have any other medical conditions.
  • are a male, and you and your female partner are trying to conceive a baby. You should not take SOLODYN\.
  • are pregnant or plan to become pregnant. SOLODYN may harm your unborn baby. Taking SOLODYN while you are pregnant may cause serious side effects on the growth of bone and teeth of your baby. Talk to your doctor before taking SOLODYN if you plan to become pregnant, or if you are already taking SOLODYN and plan to become pregnant. Stop taking SOLODYN and call your doctor right away if you become pregnant while taking SOLODYN.
  • are breastfeeding or plan to breastfeed. SOLODYN passes into your milk and may harm your baby. You and your doctor should decide if you will take SOLODYN or breastfeed. You should not do both.

Tell your doctor about all the other medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. SOLODYN® may affect the way other medicines work, and other medicines may affect how SOLODYN® works.

Especially tell your doctor if you take:

  • birth control pills. SOLODYN® may make your birth control pills less effective. You could become pregnant. You should use a second form of birth control while taking SOLODYN®.
  • a blood thinner medicine.
  • a penicillin antibiotic medicine. SOLODYN® and penicillins should not be used together.
  • antacids that contain aluminum, calcium, or magnesium or iron-containing products.
  • an acne medicine that contains isotretinoin (Amnesteem, Claravis, Sotret). SOLODYN® and isotretinoin should not be used together.

Ask your doctor or pharmacist if you are not sure if your medicine is one that is listed above.

Know the medicines you take. Keep a list of them to show your doctor and pharmacist.

How should I take SOLODYN?

  • Take SOLODYN exactly as your doctor tells you.
  • Skipping doses or not taking all doses of SOLODYN may:
    • make the treatment not work as well.
    • increase the chance that the bacteria will become resistant to SOLODYN.
  • SOLODYN can be taken with or without food. Taking SOLODYN with food may lower your chances of getting irritation or ulcers in your esophagus. Your esophagus is the tube that connects your mouth to your stomach.
  • Swallow SOLODYN Tablets whole. Do not chew, crush, or split the tablets.

If you take too much SOLODYN, call your doctor or poison control center right away. Your doctor may do blood tests to check you for side effects during treatment with SOLODYN.

What should I avoid while taking SOLODYN?

  • Avoid sunlight, sunlamps, and tanning beds. SOLODYN can make your skin sensitive to the sun and the light from sunlamps and tanning beds. You could get severe sunburn.
  • Protect your skin while out in sunlight.
  • You should not drive or operate dangerous machinery until you know how SOLODYN affects you. SOLODYN may cause you to feel dizzy or lightheaded, or have a spinning feeling (vertigo).

What are possible side effects of SOLODYN?

SOLODYN may cause serious side effects, including:

  • Harm to an unborn baby. See "What should I tell my doctor before taking SOLODYN?"
  • Permanent teeth discoloration. SOLODYN may permanently turn a baby or child's teeth yellow-grey-brown during tooth development. SOLODYN should not be used during tooth development. Tooth development happens in the last half of pregnancy, and from birth to 8 years of age. See "What should I tell my doctor before taking SOLODYN?"
  • Intestine infection (pseudomembranous colitis). Pseudomembranous colitis can happen with most antibiotics, including SOLODYN. Call your doctor right away if you get watery diarrhea, diarrhea that does not go away, or bloody stools.
  • Serious liver problems. Stop taking SOLODYN and call your doctor right away if you get any of the following symptoms of liver problems:
    • loss of appetite
    • tiredness
    • diarrhea
    • yellowing of your skin or the whites of your eyes
    • unexplained bleeding
    • confusion
    • sleepiness
  • Central nervous system effects. See "What should I avoid while taking SOLODYN?" Central nervous system effects such as light headedness, dizziness, and a spinning feeling (vertigo) may go away during your treatment with SOLODYN or if treatment is stopped.
  • Benign intracranial hypertension, also called pseudotumor cerebri. This is a condition where there is high pressure in the fluid around the brain. This swelling may lead to vision changes and permanent vision loss. Stop taking SOLODYN and tell your doctor right away if you have blurred vision, vision loss, or unusual headaches.
  • Immune system reactions including a lupus-like syndrome, hepatitis, and inflammation of blood or lymph vessels (vasculitis). Using SOLODYN for a long time to treat acne may cause immune system reactions. Tell your doctor right away if you get a fever, rash, joint pain, or body weakness. Your doctor may do tests to check your blood for immune system reactions.
  • Serious rash and allergic reactions. SOLODYN may cause a serious rash and allergic reactions that may affect parts of your body such as your liver, lungs, kidneys and heart. Sometimes these can lead to death.
  • Stop taking SOLODYN and get medical help right away if you have any of these symptoms:
    • skin rash, hives, sores in your mouth, or your skin blisters and peels
    • swelling of your face, eyes, lips, tongue, or throat
    • trouble swallowing or breathing
    • blood in your urine
    • fever, yellowing of the skin or the whites of your eyes, dark colored urine
    • pain on the right side of the stomach area (abdominal pain)
    • chest pain or abnormal heartbeats
    • swelling in your legs, ankles, and feet
    • darkening of your nails, skin, eyes, scars, teeth, and gums

The most common side effects of SOLODYN include:

  • headache
  • tiredness
  • dizziness or spinning feeling
  • itching

Call your doctor if you have a side effect that bothers you or that does not go away. Your doctor may do tests to check you for side effects during treatment with SOLODYN.

These are not all the side effects with SOLODYN. Ask your doctor or pharmacist for more information.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Medicis at 1-800-900-6389.

How should I store SOLODYN?

  • Store SOLODYN between 59°F to 86°F (15°C to 30°C).
  • Keep SOLODYN Tablets in the container that it comes in and keep the container tightly closed.
  • Keep SOLODYN Tablets dry.

Keep SOLODYN and all medicines out of the reach of children.

General information about SOLODYN

Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use SOLODYN for a condition for which it was not prescribed. Do not give SOLODYN to other people, even if they have the same symptoms you have. It may harm them.

This Patient Information leaflet summarizes the most important information about SOLODYN. If you would like more information, talk to your doctor. You can ask your doctor or pharmacist for information about SOLODYN that is written for health professionals.

For more information, call 1-800-550-5115.

What are the ingredients in SOLODYN?

Active ingredient: minocycline HCl.

Inactive ingredients: lactose monohydrate, hypromellose type 2910, magnesium stearate, colloidal silicon dioxide, and carnauba wax.

The 45 mg tablets also contain Opadry II Gray which contains: lactose monohydrate, hypromellose type 2910, titanium dioxide, triacetin, and iron oxide black JPE.

The 55 mg tablets also contain Opadry II Pink which contains: hypromellose type 2910, titanium dioxide, lactose monohydrate, polyethylene glycol 3350, triacetin, and FD&C Red #40.

The 65 mg tablets also contain Opadry II Blue which contains: hypromellose type 2910, lactose monohydrate, FD&C Blue #1, polyethylene glycol 3350, FD&C Blue #2, titanium dioxide, triacetin, and D&C Yellow #10.

The 80 mg tablets also contain Opadry II Gray which contains: hypromellose type 2910, lactose monohydrate, polyethylene glycol 3350, FD&C Blue #2, FD&C Red #40, titanium dioxide, triacetin, and FD&C Yellow #6.

The 90 mg tablets also contain Opadry II Yellow which contains: hypromellose type 2910, lactose monohydrate, titanium dioxide, iron oxide yellow, polyethylene glycol 3350, and triacetin.

The 105 mg tablets also contain Opadry II Purple which contains: hypromellose type 2910, lactose monohydrate, titanium dioxide, D&C Red #27, polyethylene glycol 3350, triacetin, and FD&C Blue #1.

The 115 mg tablets also contain Opadry II Green which contains: hypromellose type 2910, lactose monohydrate NF, D&C Yellow #10, triacetin, FD&C Blue #1, titanium dioxide, FD&C Blue #2.

The 135 mg tablets also contain Opadry II Pink which contains: hypromellose type 2910, lactose monohydrate, titanium dioxide, polyethylene glycol 3350, iron oxide red, and triacetin.

SOLODYN® is manufactured by WellSpring Pharmaceutical Canada Corp. for Medicis Pharmaceutical Corporation, Scottsdale, Arizona, 85256.

This Patient Information has been approved by the U.S. Food and Drug Administration.

SPL UNCLASSIFIED SECTION

Revised: 03/2011

U.S. Patent 5,908,838, U.S. Patent 7,790,705 and Patents Pending1

© 2010 Medicis Pharmaceutical Corporation
SOLODYN is a registered trademark of Medicis Pharmaceutical Corporation.
All other trademarks are the properties of their respective owners.

Manufactured for:
Medicis, The Dermatology Company
Scottsdale, AZ 85256
Manufactured by:
WellSpring Pharmaceutical Canada Corp.
Oakville, Ontario, CANADA L6H 1M5
N4605D

1 90 mg is also covered by U.S. Patents 7,541,347 and 7,544,373

SPL UNCLASSIFIED SECTION

Relabeling and Repackaging by:
Physicians Total Care, Inc.
Tulsa, OK      74146

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PRINCIPAL DISPLAY PANEL - 80 mg Bottle Label


Rx Only

SOLODYN®
(MINOCYCLINE HCl, USP)
EXTENDED RELEASE TABLETS

80 mg*

PRINCIPAL DISPLAY PANEL - 80 mg Bottle Label
PRINCIPAL DISPLAY PANEL - 80 mg Bottle Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1013665minocycline HCl 80 MG 24HR Extended Release Oral TabletPSN1
1014024SOLODYN 80 MG 24HR Extended Release Oral TabletPSN1
101402424 HR minocycline 80 MG Extended Release Oral Tablet [Solodyn]SBD1
101366524 HR minocycline 80 MG Extended Release Oral TabletSCD1
101402424 HR Solodyn 80 MG Extended Release Oral TabletSY1
1013665minocycline 80 MG 24 HR Extended Release Oral TabletSY1
1014024Solodyn (minocycline hydrochloride) 80 MG 24 HR Extended Release Oral TabletSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
MINOCYCLINE Pharmacologic Class Indexing3Indexing - Pharmacologic Class20230112

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d9c90ddb-dcc8-42af-a94b-505e4488bdc7Product name120250623
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
9e423e97-a6d9-7bb0-0dcb-343af7c0ff92Product name220230322
472a6924-c7ed-850b-32ce-a510e887fbf9Product name420230207
f1239550-2d2e-44c3-aec7-14fd9b4ab55dProduct name120201103
7a57513a-a145-4b95-9165-1e0ef21d6017Product name120200326
70555e58-6951-4421-9354-f80c6ce0d92cProduct name720200204
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
23de08d7-aa4e-ec8b-ce6d-2124a855e4efProduct name520180605
76736e48-254d-4a39-993d-206efbdaad1dProduct name120170717
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
0c498039-5512-d9d7-e6b6-833de47219ffProduct name220151106
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
d723478e-ad4a-ec23-6bd7-cfe33e1e3840Product name120140508

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54868-6285-0Solodyn30 in 1 BOTTLETABLET, FILM COATED, EXTENDED RE301

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54868-6285SOLODYN (MINOCYCLINE HYDROCHLORIDE) TABLET, FILM COATED, EXTENDED RELEASE [PHYSICIANS TOTAL CARE, INC.]11 package rows20110726_6ade9be7-f10f-40b2-b5c5-39c5aef3a83d.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54868-6285-0EA - Each54868-628510b9896b-c5a8-454f-9f91-577a3b23ced512015-10-02
99207-466-30EA - Each99207-466ab4d9310-637b-4e15-aeb6-25edc737580c12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
minocycline hydrochlorideACTIVE INGREDIENT0020414E5U1
minocyclineACTIVE MOIETYFYY3R43WGO1
FD&C Blue No. 2INACTIVE INGREDIENTL06K8R7DQK1
FD&C Red No. 40INACTIVE INGREDIENTWZB9127XOA1
FD&C Yellow No. 6INACTIVE INGREDIENTH77VEI93A81
hypromellose 2910 (50 mpa.s)INACTIVE INGREDIENT1IVH67816N1
lactose monohydrateINACTIVE INGREDIENTEWQ57Q8I5X1
polyethylene glycol 3350INACTIVE INGREDIENTG2M7P15E5P1
titanium dioxideINACTIVE INGREDIENT15FIX9V2JP1
triacetinINACTIVE INGREDIENTXHX3C3X6731

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54868-628554868-6285-0
99207-466

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 193 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
FD&C Red No. 40FD&C RED NO. 40WZB9127XOACAPSULE, COATED PELLETS / ORALNAExact identifier — unii candidate
28 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XTABLET / SUBLINGUAL505 mgExact identifier — unii candidate
38 equally ranked IID candidates
polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5POINTMENT / TOPICAL1179 mgExact identifier — unii candidate
28 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS690 mgExact identifier — unii candidate
38 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOATABLET, FILM COATED / ORAL2.5 mgExact identifier — unii candidate
28 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION / SUBCUTANEOUS98 mgExact identifier — unii candidate
38 equally ranked IID candidates
FD&C Yellow No. 6FD&C YELLOW NO. 6H77VEI93A8CAPSULE, EXTENDED RELEASE / ORAL4.59 mgExact identifier — unii candidate
34 equally ranked IID candidates
polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION / INTRAVENOUS0.5 mlExact identifier — unii candidate
28 equally ranked IID candidates
polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION, SUSPENSION / SOFT TISSUE87 mgExact identifier — unii candidate
28 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XPOWDER, FOR SUSPENSION / ORALNAExact identifier — unii candidate
38 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPTABLET / ORAL232 mgExact identifier — unii candidate
40 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOAPOWDER, FOR SUSPENSION / ORAL3 mgExact identifier — unii candidate
28 equally ranked IID candidates
FD&C Blue No. 2FD&C BLUE NO. 2L06K8R7DQKCAPSULE, DELAYED RELEASE / ORAL0.22 mgExact identifier — unii candidate
11 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673CAPSULE, DELAYED RELEASE / ORAL5.1 mgExact identifier — unii candidate
14 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOASYRUP / ORAL3 mgExact identifier — unii candidate
28 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS9.5 %w/vExact identifier — unii candidate
38 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPTABLET, EXTENDED RELEASE / ORAL90 mgExact identifier — unii candidate
40 equally ranked IID candidates
FD&C Yellow No. 6FD&C YELLOW NO. 6H77VEI93A8LOTION / TOPICALNAExact identifier — unii candidate
34 equally ranked IID candidates
polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PTABLET, CHEWABLE / ORAL15 mgExact identifier — unii candidate
28 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XCAPSULE, DELAYED RELEASE / ORAL2087 mgExact identifier — unii candidate
38 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPCAPSULE, COATED PELLETS / ORAL4.4 mgExact identifier — unii candidate
40 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XTABLET, EXTENDED RELEASE / ORAL2575 mgExact identifier — unii candidate
38 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS107 mgExact identifier — unii candidate
38 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOAPOWDER, FOR SOLUTION / ORAL0.33 mg/5mlExact identifier — unii candidate
28 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XTABLET, COATED / ORAL1301 mgExact identifier — unii candidate
38 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR150 mgExact identifier — unii candidate
38 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673CONCENTRATE / ORAL250 mgExact identifier — unii candidate
14 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XTABLET / ORAL4384 mgExact identifier — unii candidate
38 equally ranked IID candidates
polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PINJECTION, SUSPENSION / SUBCUTANEOUS2.88 %w/vExact identifier — unii candidate
28 equally ranked IID candidates
FD&C Yellow No. 6FD&C YELLOW NO. 6H77VEI93A8CAPSULE / ORAL7 mgExact identifier — unii candidate
34 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOASPONGE / TOPICALNAExact identifier — unii candidate
28 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPFILM, SOLUBLE / ORAL2 mgExact identifier — unii candidate
40 equally ranked IID candidates
FD&C Blue No. 2FD&C BLUE NO. 2L06K8R7DQKCAPSULE / ORAL4 mgExact identifier — unii candidate
11 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673CAPSULE, EXTENDED RELEASE / ORAL467 mgExact identifier — unii candidate
14 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION / INTRAVENOUS900 mgExact identifier — unii candidate
38 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOATABLET / ORAL4 mgExact identifier — unii candidate
28 equally ranked IID candidates
polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PSPRAY, METERED / NASAL96 mgExact identifier — unii candidate
28 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPSUPPOSITORY, EXTENDED RELEASE / INTRAUTERINE1 mgExact identifier — unii candidate
40 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XTABLET, FOR SUSPENSION / ORAL2794 mgExact identifier — unii candidate
38 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOASUSPENSION/ DROPS / ORAL1 mgExact identifier — unii candidate
28 equally ranked IID candidates
FD&C Blue No. 2FD&C BLUE NO. 2L06K8R7DQKTABLET, DELAYED RELEASE / ORAL0.2 mgExact identifier — unii candidate
11 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOACAPSULE, COATED, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
28 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL42 mgExact identifier — unii candidate
40 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPCAPSULE / RESPIRATORY (INHALATION)NAExact identifier — unii candidate
40 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XTABLET / BUCCAL43 mgExact identifier — unii candidate
38 equally ranked IID candidates
FD&C Yellow No. 6FD&C YELLOW NO. 6H77VEI93A8POWDER, FOR SOLUTION / ORAL45 mgExact identifier — unii candidate
34 equally ranked IID candidates
FD&C Blue No. 2FD&C BLUE NO. 2L06K8R7DQKTABLET, CHEWABLE / ORAL3 mgExact identifier — unii candidate
11 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673TABLET, CHEWABLE, EXTENDED RELEASE / ORAL2 mgExact identifier — unii candidate
14 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOASOLUTION / DENTALNAExact identifier — unii candidate
28 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPPOWDER / RESPIRATORY (INHALATION)2 mgExact identifier — unii candidate
40 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XGRANULE / ORAL8946 mgExact identifier — unii candidate
38 equally ranked IID candidates
polyethylene glycol 3350POLYETHYLENE GLYCOL 3350G2M7P15E5PSUSPENSION / SUBCUTANEOUS2.88 %w/vExact identifier — unii candidate
28 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673TABLET, DELAYED RELEASE / ORAL23 mgExact identifier — unii candidate
14 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XCAPSULE, EXTENDED RELEASE / ORAL5364 mgExact identifier — unii candidate
38 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPCAPSULE, DELAYED RELEASE / ORAL55 mgExact identifier — unii candidate
40 equally ranked IID candidates
FD&C Red No. 40FD&C RED NO. 40WZB9127XOATABLET, EXTENDED RELEASE / ORAL2.22 mgExact identifier — unii candidate
28 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPTABLET, FILM COATED, EXTENDED RELEASE / ORAL11 mgExact identifier — unii candidate
40 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPTABLET, FILM COATED / ORAL36 mgExact identifier — unii candidate
40 equally ranked IID candidates
lactose monohydrateLACTOSE MONOHYDRATEEWQ57Q8I5XINJECTION / INTRAMUSCULAR150 mgExact identifier — unii candidate
38 equally ranked IID candidates
titanium dioxideTITANIUM DIOXIDE15FIX9V2JPGEL / TOPICAL0.06 %w/wExact identifier — unii candidate
40 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 8 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N050808-001SOLODYNMINOCYCLINE HYDROCHLORIDEEQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08
N050808-002SOLODYNMINOCYCLINE HYDROCHLORIDEEQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08
N050808-003SOLODYNMINOCYCLINE HYDROCHLORIDEEQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08
N050808-004SOLODYNMINOCYCLINE HYDROCHLORIDEEQ 65MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-23
N050808-005SOLODYNMINOCYCLINE HYDROCHLORIDEEQ 115MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-23
N050808-006SOLODYNMINOCYCLINE HYDROCHLORIDEEQ 105MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27
N050808-007SOLODYNMINOCYCLINE HYDROCHLORIDEEQ 80MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27
N050808-008SOLODYNMINOCYCLINE HYDROCHLORIDEEQ 55MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27

Orange Book patents#

Current patent rows page 1 of 1 · 12 matching rows.

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N050808-00179194832027-03-07U-1078
N050808-00279194832027-03-07U-1078
N050808-00275413472027-04-02U-917
N050808-00275443732027-04-02Drug product
N050808-00379194832027-03-07U-1078
N050808-00479194832027-03-07U-1078
N050808-00491926152031-11-17Drug product2016-01-08
N050808-00579194832027-03-07U-1078
N050808-00591926152031-11-17Drug product2016-01-08
N050808-00679194832027-03-07U-1078
N050808-00779194832027-03-07U-1078
N050808-00879194832027-03-07U-1078

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 9 · 360 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N050808-001SOLODYNEQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-002SOLODYNEQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-003SOLODYNEQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-004SOLODYNEQ 65MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-23d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-005SOLODYNEQ 115MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-23d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-006SOLODYNEQ 105MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-007SOLODYNEQ 80MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-008SOLODYNEQ 55MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27d4dbc9d85df4…
2026-10-15 13:18:302026-09N050808-001SOLODYNEQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08c2088c7a36db…
2026-10-15 13:18:302026-09N050808-002SOLODYNEQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08c2088c7a36db…
2026-10-15 13:18:302026-09N050808-003SOLODYNEQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08c2088c7a36db…
2026-10-15 13:18:302026-09N050808-004SOLODYNEQ 65MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-23c2088c7a36db…
2026-10-15 13:18:302026-09N050808-005SOLODYNEQ 115MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-23c2088c7a36db…
2026-10-15 13:18:302026-09N050808-006SOLODYNEQ 105MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27c2088c7a36db…
2026-10-15 13:18:302026-09N050808-007SOLODYNEQ 80MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27c2088c7a36db…
2026-10-15 13:18:302026-09N050808-008SOLODYNEQ 55MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27c2088c7a36db…
2026-09-14 22:38:342026-08N050808-001SOLODYNEQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-0884e616aacf4f…
2026-09-14 22:38:342026-08N050808-002SOLODYNEQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-0884e616aacf4f…
2026-09-14 22:38:342026-08N050808-003SOLODYNEQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-0884e616aacf4f…
2026-09-14 22:38:342026-08N050808-004SOLODYNEQ 65MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-2384e616aacf4f…
2026-09-14 22:38:342026-08N050808-005SOLODYNEQ 115MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-2384e616aacf4f…
2026-09-14 22:38:342026-08N050808-006SOLODYNEQ 105MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-2784e616aacf4f…
2026-09-14 22:38:342026-08N050808-007SOLODYNEQ 80MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-2784e616aacf4f…
2026-09-14 22:38:342026-08N050808-008SOLODYNEQ 55MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-2784e616aacf4f…
2026-08-18 06:07:402026-07N050808-001SOLODYNEQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08caaa826d4ba7…
2026-08-18 06:07:402026-07N050808-002SOLODYNEQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08caaa826d4ba7…
2026-08-18 06:07:402026-07N050808-003SOLODYNEQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08caaa826d4ba7…
2026-08-18 06:07:402026-07N050808-004SOLODYNEQ 65MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-23caaa826d4ba7…
2026-08-18 06:07:402026-07N050808-005SOLODYNEQ 115MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-23caaa826d4ba7…
2026-08-18 06:07:402026-07N050808-006SOLODYNEQ 105MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27caaa826d4ba7…
2026-08-18 06:07:402026-07N050808-007SOLODYNEQ 80MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27caaa826d4ba7…
2026-08-18 06:07:402026-07N050808-008SOLODYNEQ 55MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N050808-001SOLODYNEQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08011fe1cb6892…
2026-02-19 14:30 UTC2026-02N050808-002SOLODYNEQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08011fe1cb6892…
2026-02-19 14:30 UTC2026-02N050808-003SOLODYNEQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2006-05-08011fe1cb6892…
2026-02-19 14:30 UTC2026-02N050808-004SOLODYNEQ 65MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-23011fe1cb6892…
2026-02-19 14:30 UTC2026-02N050808-005SOLODYNEQ 115MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2009-07-23011fe1cb6892…
2026-02-19 14:30 UTC2026-02N050808-006SOLODYNEQ 105MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27011fe1cb6892…
2026-02-19 14:30 UTC2026-02N050808-007SOLODYNEQ 80MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27011fe1cb6892…
2026-02-19 14:30 UTC2026-02N050808-008SOLODYNEQ 55MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**TABLET, EXTENDED RELEASE / ORALRLD2010-08-27011fe1cb6892…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 4 · 140 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N050808-004AB11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N050808-005AB11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N050808-006AB11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N050808-007AB11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N050808-008AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N050808-004AB18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N050808-005AB18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N050808-006AB18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N050808-007AB18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N050808-008AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N050808-004AB15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N050808-005AB15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N050808-006AB15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N050808-007AB15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N050808-008AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N050808-004AB15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N050808-005AB15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N050808-006AB15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N050808-007AB15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N050808-008AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N050808-004AB14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N050808-005AB14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N050808-006AB14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N050808-007AB14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N050808-008AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N050808-004AB174a2ff9319b5…
2019-12-13 00:20 UTC2019-12N050808-005AB174a2ff9319b5…
2019-12-13 00:20 UTC2019-12N050808-006AB174a2ff9319b5…
2019-12-13 00:20 UTC2019-12N050808-007AB174a2ff9319b5…
2019-12-13 00:20 UTC2019-12N050808-008AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N050808-004AB1bb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N050808-005AB1bb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N050808-006AB1bb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N050808-007AB1bb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N050808-008AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N050808-004AB1782e0a99824c…
2021-12-28 21:50 UTC2021-12N050808-005AB1782e0a99824c…
2021-12-28 21:50 UTC2021-12N050808-006AB1782e0a99824c…
2021-12-28 21:50 UTC2021-12N050808-007AB1782e0a99824c…
2021-12-28 21:50 UTC2021-12N050808-008AB1782e0a99824c…

Observed Orange Book patent history#

Patent history page 1 of 40 · 1,593 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2026-11-14 07:37:172026-10N050808-00179194832027-03-07U-1078d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00279194832027-03-07U-1078d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00275413472027-04-02U-917d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00275443732027-04-02Drug productd4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00379194832027-03-07U-1078d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00479194832027-03-07U-1078d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00491926152031-11-17Drug product2016-01-08d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00579194832027-03-07U-1078d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00591926152031-11-17Drug product2016-01-08d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00679194832027-03-07U-1078d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00779194832027-03-07U-1078d4dbc9d85df4…
2026-11-14 07:37:172026-10N050808-00879194832027-03-07U-1078d4dbc9d85df4…
2026-10-15 13:18:302026-09N050808-00179194832027-03-07U-1078c2088c7a36db…
2026-10-15 13:18:302026-09N050808-00279194832027-03-07U-1078c2088c7a36db…
2026-10-15 13:18:302026-09N050808-00275413472027-04-02U-917c2088c7a36db…
2026-10-15 13:18:302026-09N050808-00275443732027-04-02Drug productc2088c7a36db…
2026-10-15 13:18:302026-09N050808-00379194832027-03-07U-1078c2088c7a36db…
2026-10-15 13:18:302026-09N050808-00479194832027-03-07U-1078c2088c7a36db…
2026-10-15 13:18:302026-09N050808-00491926152031-11-17Drug product2016-01-08c2088c7a36db…
2026-10-15 13:18:302026-09N050808-00579194832027-03-07U-1078c2088c7a36db…
2026-10-15 13:18:302026-09N050808-00591926152031-11-17Drug product2016-01-08c2088c7a36db…
2026-10-15 13:18:302026-09N050808-00679194832027-03-07U-1078c2088c7a36db…
2026-10-15 13:18:302026-09N050808-00779194832027-03-07U-1078c2088c7a36db…
2026-10-15 13:18:302026-09N050808-00879194832027-03-07U-1078c2088c7a36db…
2026-09-14 22:38:342026-08N050808-00179194832027-03-07U-107884e616aacf4f…
2026-09-14 22:38:342026-08N050808-00279194832027-03-07U-107884e616aacf4f…
2026-09-14 22:38:342026-08N050808-00275413472027-04-02U-91784e616aacf4f…
2026-09-14 22:38:342026-08N050808-00275443732027-04-02Drug product84e616aacf4f…
2026-09-14 22:38:342026-08N050808-00379194832027-03-07U-107884e616aacf4f…
2026-09-14 22:38:342026-08N050808-00479194832027-03-07U-107884e616aacf4f…
2026-09-14 22:38:342026-08N050808-00491926152031-11-17Drug product2016-01-0884e616aacf4f…
2026-09-14 22:38:342026-08N050808-00579194832027-03-07U-107884e616aacf4f…
2026-09-14 22:38:342026-08N050808-00591926152031-11-17Drug product2016-01-0884e616aacf4f…
2026-09-14 22:38:342026-08N050808-00679194832027-03-07U-107884e616aacf4f…
2026-09-14 22:38:342026-08N050808-00779194832027-03-07U-107884e616aacf4f…
2026-09-14 22:38:342026-08N050808-00879194832027-03-07U-107884e616aacf4f…
2026-08-18 06:07:402026-07N050808-00179194832027-03-07U-1078caaa826d4ba7…
2026-08-18 06:07:402026-07N050808-00279194832027-03-07U-1078caaa826d4ba7…
2026-08-18 06:07:402026-07N050808-00275413472027-04-02U-917caaa826d4ba7…
2026-08-18 06:07:402026-07N050808-00275443732027-04-02Drug productcaaa826d4ba7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
492810e2-d2ef-4f32-99e7-4d670bb48acf6ade9be7-f10f-40b2-b5c5-39c5aef3a83d2011-04-04Warnings, Adverse reactionsExact identifier
spl id: 492810e2-d2ef-4f32-99e7-4d670bb48acf
spl set id: 6ade9be7-f10f-40b2-b5c5-39c5aef3a83d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.